Tirzepatide
Dual GIP and GLP-1 Receptor Agonist
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Available as FDA-approved Mounjaro® for Type 2 diabetes and Zepbound® for weight management and obstructive sleep apnea. It provides superior weight loss and glycemic control compared to single-pathway medications through its unique dual mechanism of action.
Complete Dosing Guide
Quick Reference
Administration Method
Subcutaneous injection once weekly
Step-by-Step Dosing Protocol
Dosing Guidelines
Standard escalation begins with 2.5 mg weekly for 4 weeks, followed by 5 mg weekly for 4 weeks. Further increases to 7.5 mg, 10 mg, 12.5 mg, and maximum 15 mg weekly should occur at 4-week intervals based on clinical response and tolerability. For diabetes management, maintenance doses of 5-15 mg weekly are typical. For weight management, most patients achieve optimal results at 10-15 mg weekly.
You always start low and go slow with Tirzepatide. Everyone starts with 2.5mg once a week for a month. Then you increase by 2.5mg every month until you find the dose that works best for you, up to 15mg per week maximum. Most people end up taking 10-15mg per week for the best weight loss results. The slow increase helps your body get used to it and reduces side effects.
Mixing & Injection
Subcutaneous injection using pre-filled pens (KwikPen™) or vials with separate syringes. Injection sites include abdomen, thigh, or upper arm. Rotate injection sites weekly to prevent lipodystrophy. Administer on the same day each week, any time of day, with or without meals. If dose is missed, administer as soon as possible if within 4 days, otherwise skip and resume regular schedule.
Subcutaneous injection using pre-filled pens (KwikPen™) or vials with separate syringes. Injection sites include abdomen, thigh, or upper arm. Rotate injection sites weekly to prevent lipodystrophy. Administer on the same day each week, any time of day, with or without meals. If dose is missed, administer as soon as possible if within 4 days, otherwise skip and resume regular schedule.
Clinical Administration Guidelines
Injection Protocol
- •Subcutaneous injection once weekly
- •Rotate between abdomen, thigh, upper arm
- •Same time weekly (any time of day)
- •Can be taken with or without food
Monitoring Schedule
- •Weekly weight and glucose monitoring
- •Monthly HbA1c and cardiovascular markers
- •Regular comprehensive metabolic panels
- •STOP if severe GI symptoms or pancreatitis signs
Dosage Calculator
Medical Disclaimer
Tirzepatide is FDA-approved as Mounjaro® for Type 2 diabetes and Zepbound® for chronic weight management. This information is for educational purposes and should not replace consultation with healthcare providers. Individual results may vary. Prescribing information and medical supervision are required for all therapeutic uses.